NGF and Down syndrome: This hypothesis is supported by decreases in tissue plasminogen activator and plasmin, which can process proNGF, and increases in the NGF degradative enzyme MMP-9 in MCI and in Down’s syndrome (Bruno et al., 2009a,b; Iulita et al., 2014).